Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358548 · ClinicalTrials.gov registry record · Phase 2
ATATcH Alternating Treatment Plans for Advanced Cancer
A Phase 2 study of Lung Cancer and Head and Neck Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 11
- Study locations
NCT05358548 is a Phase 2 study of Lung Cancer and Head and Neck Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 150 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 11 study locations across 1 state.
The verdict
NCT05358548, a Phase 2 study of Lung Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG 5Fluorouracil
Study Locations (11)
New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Elizabeth
- Cancer Institute of New Jersey at Hamilton - Hamilton
- RWJBarnabas Health - Jersey City - Jersey City
- RWJBarnabas Health - Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Saint Barnabas Medical Center - Livingston
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- RWJ Barnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
- Robert Wood Johnson Somerset Hospital - Somerville
- RWJBarnabas Health - Community Medical Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05358548
The ClinicalTrials.gov registry entry for NCT05358548 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05358548 reports 11 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05358548 about?
NCT05358548 is a clinical study titled "ATATcH Alternating Treatment Plans for Advanced Cancer". The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
What is the current status of trial NCT05358548?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-04-28. Estimated completion is 2025-12-01.
What conditions does trial NCT05358548 study?
This clinical trial studies the following conditions: Lung Cancer, Head and Neck Cancer.
What interventions are being tested in trial NCT05358548?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), 5Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT05358548?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05358548 being conducted?
This trial has 11 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.